# Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

Source: https://onco.cc/trials/nct04844866/  
OnCo record `nct04844866` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zamtocabtagene autoleucel, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by Miltenyi Biomedicine GmbH, now recruiting.

## Summary

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients is a phase 2 interventional study registered as NCT04844866 by Miltenyi Biomedicine GmbH, with 213 participants planned, started 2021-08-18 and due to reach its primary completion in 2025-01-15. Interventions recorded: MB-CART2019.1, Standard of Care. Conditions listed: Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04844866
- Phase: 2
- Setting: A Pivotal Phase II Randomised, Multi-centre, Open-label Study to Evaluate the Efficacy and Safety of MB-CART2019.1 Compared to SoC Therapy in Participants With r/r DLBCL, Who Are Not Eligible for HDC and ASCT
- Sponsor: Miltenyi Biomedicine GmbH
- Enrolled: 213

## Sources

- ClinicalTrials.gov NCT04844866: https://clinicaltrials.gov/study/NCT04844866

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Bendamustine](https://onco.cc/drugs/bendamustine/), [CAPOX (capecitabine, oxaliplatin)](https://onco.cc/drugs/capox/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Polatuzumab vedotin](https://onco.cc/drugs/polatuzumab-vedotin/), [Rituximab](https://onco.cc/drugs/rituximab/), [Zamtocabtagene autoleucel](https://onco.cc/drugs/zamtocabtagene-autoleucel/)
- companies: [Miltenyi Biomedicine](https://onco.cc/companies/miltenyi-biomedicine/)

---
JSON: https://onco.cc/api/v1/entities/nct04844866.json